Abstract: The present disclosure discloses a three-dimensional automatic location system for an epileptogenic focus based on deep learning. The system includes: a PET image acquisition and labelling module; a registration module mapping PET image to standard symmetrical brain template; a PET image preprocessing module generating mirror image pairs of left and right brain image blocks; a network SiameseNet training module containing two deep residual convolutional neural networks which share weight parameters, an output layer connecting a multilayer perceptron and a softmax layer, and using a training set of an epileptogenic focus image and an normal image to train the network to obtain a network model; a classification module and epileptogenic focus location module, using the trained network model to generate a probabilistic heatmap for the newly input PET image, a classifier determining whether the image is normal or epileptogenic focus sample, and then predicting a position for the epileptogenic focus region.

Abstract: The present disclosure discloses a three-dimensional automatic location system for an epileptogenic focus based on deep learning. The system includes: a PET image acquisition and labelling module; a registration module mapping PET image to standard symmetrical brain template; a PET image preprocessing module generating mirror image pairs of left and right brain image blocks; a network SiameseNet training module containing two deep residual convolutional neural networks which share weight parameters, an output layer connecting a multilayer perceptron and a softmax layer, and using a training set of an epileptogenic focus image and an normal image to train the network to obtain a network model; a classification module and epileptogenic focus location module, using the trained network model to generate a probabilistic heatmap for the newly input PET image, a classifier determining whether the image is normal or epileptogenic focus sample, and then predicting a position for the epileptogenic focus region.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of conditions which involve the lymphatic system of the subject, and may also present a disease state in the brain of the subject. Methods of treating diseases involving the lymphatic system and pharmaceutical compositions are also disclosed.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads have dual functionality that may permit treatment of diseases in a subject other than diseases that present in the brain, e.g., solid tumors in the body. Methods of treating various diseases and pharmaceutical compositions are also disclosed.

Abstract: Provided are compositions and methods related to the co-administration of an immunoglobulin Fc region-containing polypeptide and a central nervous system (CNS)-targeted antibody or Fc-fusion polypeptide conjugate, to improve pharmacokinetics and/or delivery of the conjugate across the blood-brain barrier (BBB). Also provided are methods of treatment of indications and diseases of the CNS and indications and diseases with a CNS component.

Abstract: In one embodiment, a method is provided. The method includes selecting, with a communications management system, a first satellite communications (SATCOM) system of a plurality of SATCOM systems as a primary SATCOM system based on user input, received by a human machine interface, that identifies the first SATCOM system as a user-selected SATCOM system. The method further includes automatically switching, with the communications management system, the primary SATCOM system from the first SATCOM system to a second SATCOM system of the plurality of SATCOM systems in response to: a fault status for the first SATCOM system; a loss of channel availability for the first SATCOM system; and/or a failed datalink message transmission for the first SATCOM system. The method further includes establishing a communication link between the primary SATCOM system and a ground station.

Abstract: In one embodiment, a method is provided. The method includes selecting, with a communications management system, a first satellite communications (SATCOM) system of a plurality of SATCOM systems as a primary SATCOM system based on user input, received by a human machine interface, that identifies the first SATCOM system as a user-selected SATCOM system. The method further includes automatically switching, with the communications management system, the primary SATCOM system from the first SATCOM system to a second SATCOM system of the plurality of SATCOM systems in response to: a fault status for the first SATCOM system; a loss of channel availability for the first SATCOM system; and/or a failed datalink message transmission for the first SATCOM system. The method further includes establishing a communication link between the primary SATCOM system and a ground station.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of frontotemportal dementia (FTD). Methods of treating frontotemporal dementia (FTD) and pharmaceutical compositions are also disclosed.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of Lewy body dementia. Methods of treating Lewy body dementia and pharmaceutical compositions are also disclosed.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of Gaucher disease. Methods of treating Gaucher disease and pharmaceutical compositions are also disclosed.

Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads have dual functionality that may permit treatment of diseases in a subject other than diseases that present in the brain, e.g., solid tumors in the body. Methods of treating various diseases and pharmaceutical compositions are also disclosed.

Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.

Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.

Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.

Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.